CD274 and neoplasm: Biomarkers such as PD-L1 expression levels, TMB, MSI, or tumor inflammation can not only help us screen populations who can benefit from immunotherapy but also avoid unnecessary costs and possible severe toxicity in those unresponsive to treatment.